Mostrar el registro sencillo del ítem
Caracterización de pacientes con co - infeccion VIH - Tuberculosis tratados con raltegravir en el Hospital Militar Central
| dc.contributor.advisor | Morales, Carlos | spa |
| dc.contributor.author | Quiñónez, Juan | |
| dc.coverage.spatial | Medicina | spa |
| dc.date.accessioned | 2016-01-21T17:06:02Z | |
| dc.date.accessioned | 2019-12-30T19:03:37Z | |
| dc.date.available | 2016-01-21T17:06:02Z | |
| dc.date.available | 2019-12-30T19:03:37Z | |
| dc.date.issued | 2015-12-15 | |
| dc.identifier.uri | http://hdl.handle.net/10654/7238 | |
| dc.description.abstract | La infección por virus de inmunodeficiencia humana emerge ante el mundo desde su descripción en 1987 como una infección altamente prevalente con una incidencia reportada en crecimiento; se estima que para el 2012, 35 millones de personas estaban infectadas por el virus (1). En Colombia se estima, según datos del ministerio de salud, que 41900 personas padecen de la infección, esta cifra podría alcanzar los 120000 infectados considerando el habitual sub registro en nuestra región. En esta población se considera con frecuencia la presencia de co infección VIH – TBC (tuberculosis), en un rango que oscila entre 8 – 30% de acuerdo a datos de estudios poblacionales (2). Dados los considerables avances en terapéutica en la infección por VIH el pronóstico vital ha mejorado considerablemente desde a descripción inicial de la enfermedad hasta el día de hoy; sin embargo, la resistencia a los anti retrovirales debido a las mutaciones en el virus siguen siendo un problema frecuente. En este contexto, en el 2007 es aprobado por la FDA el raltegravir como terapia para la infección por VIH demostrando efectividad en el tratamiento de pacientes tanto NAIVE como experimentados. Existen escasas dudas acerca del comportamiento farmacocinético de raltegravir y por ende en los desenlaces clínicos de esta terapia en pacientes con co-infección. El hospital militar central se erige, de acuerdo al tipo de población que maneja, como centro de referencia a nivel nacional para tratamiento de todo tipo de enfermedades, entre ellas la co-infección VIH – TBC; y es uno de los primeros centros a nivel nacional en contar con raltegravir como tratamiento de infección por VIH, se pretende caracterizar la población con este tipo de terapia. | spa |
| dc.format | spa | |
| dc.language.iso | spa | spa |
| dc.publisher | Universidad Militar Nueva Granada | spa |
| dc.subject.mesh | TUBERCULOSIS PULMONAR | |
| dc.subject.mesh | INFECCIONES POR VIH | |
| dc.subject.mesh | SINDROMES DE INMUNODEFICIENCIA | |
| dc.title | Caracterización de pacientes con co - infeccion VIH - Tuberculosis tratados con raltegravir en el Hospital Militar Central | spa |
| dc.type | info:eu-repo/semantics/bachelorThesis | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.publisher.department | Facultad de Medicina | spa |
| dc.type.local | Trabajo de grado | spa |
| dc.description.abstractenglish | The infection with human immunodeficiency virus emerges to the world since its description in 1987 as a highly prevalent infection reported a growing incidence; it is estimated that by 2012, 35 million people were infected by the virus (1). In Colombia it is estimated, according to the health ministry, 41900 people suffer from this infection, this numbers could reach 120,000 infected people, considering the usual low frecuency of registry in our region. The presence of HIV co - infection with tuberculosis (TB) must be considered, it was estimated in a range between 8-30% according to data from population studies (2). Given the considerable advances in therapy in HIV infection the prognosis has improved considerably since the initial description of the disease; however, resistance to anti retroviral due to mutations in virus remains a frequent problem. In this context, FDA approved raltegravir therapy for HIV infection in 2007 by it´s demonstrated effectiveness in the treatment. There is little doubt about the pharmacokinetic behavior of raltegravir and therefore in the clinical outcomes of this therapy in patients with co-infection. El Hospital Militar Central is built, according to the type of population that manages, as a reference center at national level to treat all kinds of diseases, including HIV co-infection - TB; and is one of the first centers in Colombia have raltegravir. The purpose of this study is to characterize the population with this co - infection treated whit raltegravir. | eng |
| dc.title.translated | Characterization of patients receiving raltegravir in co-infection HIV -Tuberculosis in Hospital Militar Central | spa |
| dc.subject.keywords | VIH | spa |
| dc.subject.keywords | Tuberculosis | spa |
| dc.subject.keywords | VIH - Tuberculosis co - infection | spa |
| dc.subject.keywords | raltegravir | spa |
| dc.publisher.program | Medicina interna | spa |
| dc.creator.degreename | Especialista en Medicina Interna | spa |
| dc.relation.references | Ledergerber B, Battegay M. Epidemilogy of HIV. Therapeutische Umschau 2014; 71 (8): 437 – 41. | spa |
| dc.relation.references | Patz D. Construyendo paso a paso: guía sobre atención integral de personas que viven con la co-infección de TB/VIH en América Latina y el Caribe. Documento de trabajo. Washington, D.C.: Organización Panamericana de la Salud; 2003. | spa |
| dc.relation.references | Zumla A, Raviglione M, Hafner R, von Reyn F. Tuberculosis. N Eng J Med 2013; 368 (8): 745 – 55. | spa |
| dc.relation.references | Von Reyn CF. Optimal treatment of codisease due to HIV and tuberculosis. J Infect Dis 2011;204:817-9. | spa |
| dc.relation.references | Global tuberculosis report 2012. Geneva: World Health Organization (http://www.who.int/tb/publications/global_report/en/). | spa |
| dc.relation.references | Combs DL, O’Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity and acceptability: the report of the final results. Ann Intern Med 1990;112:397-406. | spa |
| dc.relation.references | Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011;365:1492-501. | spa |
| dc.relation.references | Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011;365:1471-81. | spa |
| dc.relation.references | WHO policy on collaborative TB/HIV activities. Geneva: World Health Organization, 2012 http://whqlibdoc.who.int/publications/2012/9789241503006_eng.pdf). | spa |
| dc.relation.references | Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012;157:313-24.. | spa |
| dc.relation.references | LawnSD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007;21(3):335–41. | spa |
| dc.relation.references | Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 2006;53(6):357–63. | spa |
| dc.relation.references | Pepper DJ, Marais S, Maartens G, et al. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009;48(11):e96–107. | spa |
| dc.relation.references | Summa V, Petrocchi A, Bonelli F, Crescenzi B, Donghi M, Ferrara M, Fiore F, Gardelli C, Paz O, Hazuda D, Jones P, Kinzel O, Laufer R, Monteagudo E, Muraglia E, Nizi E, Orvieto F, Pace P, Escatore G, Scarpelli R, Stillmock K, Witmer M, Rowley M. Discovery of raltegravir, a potent, elective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 2008, 51, 843−5855. | spa |
| dc.relation.references | Grinsztejn B, Nguyen B, Katlama C, Gatell J, Lazzarin A, Vittecoq D, Gonzalez C, Chen J, Harvey C, Isaacs R. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369, 1261−1269. | spa |
| dc.relation.references | Yazdanpanah Y, Fagard C, Descamps D, Taburet A, Colin C, Roquebert B, Katlama C, Pialoux G, Jacomet C, Piketty C, Bollens D, Molina J, Chêne G. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrugresistant HIV: results of the ANRS 139 TRIO trial. Clin. Infect. Dis. 2009, 49, 1441−1449. | spa |
| dc.relation.references | Thuret I, Chaix, M, Tamalet C, Reliquet V, Firtion G, Tricoire J, Rabaud C, Frange P, Aumaitre H, Blanche S, Raltegravir, etravirine and darunavir combination in adolescents with multidrug-resistant virus. AIDS 2009, 23, 2364−2366. | spa |
| dc.relation.references | McKinnell J, Lin H, Nevin C, Willig J, McFarland G, Genz M, Raper J, DeLaitsch L, Mrus J, Klaskala W, Mugavero M, Saag M. Early virologic suppression with threeclass experienced patients: 24-week effectiveness in the darunavir outcomes study. AIDS 2009, 23, 1539−1546. | spa |
| dc.relation.references | Imaz A, del Saz S, Ribas M, Curran A, Caballero E, Falcó V, Crespo M, Ocaña I, Diaz M, de Gopegui E, Riera M, Ribera E. Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. J. Acquired Immune Defic. Syndr. 2009, 52, 382−386. | spa |
| dc.relation.references | Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007; 35:1657– 1663. | spa |
| dc.relation.references | Wenning LA, Hanley WD, Brainard DM, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53:2852–2856. | spa |
| dc.relation.references | Reinbach B, de Sousa G, Dostert P, et al. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999; 121:37–48. | spa |
| dc.relation.references | Grinsztejn B, De Castro N, et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Refl ate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 2014; 14: 459–67. | spa |
| dc.subject.proposal | VIH | spa |
| dc.subject.proposal | TUBERCULOSIS | spa |
| dc.subject.proposal | CO - INFECCION VIH - TBC | spa |
| dc.subject.proposal | RALTEGRAVIR | spa |
Archivos en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Medicina Interna [38]